Sepsisul reprezintă o boală sistemică caracterizată de disfuncţia acută de organ determinată de infecţie. Diagnosticul precoce, evaluarea severităţii sepsisului, resuscitarea agresivă şi administrarea adecvată a antibioticelor sunt asociate cu o evoluţie favorabilă. O gama largă de biomarkeri au fost propuşi pentru diagnosticul sepsisului, mult mai mulţi decât în alte boli, demonstrând astfel complexitatea acestei patologii. În primul studiu ce demonstrează valoarea clinică a miRNA în sepsis , autorii au arătat că nivelurile de miR-150 la nivel leucocitar şi plasmatic sunt reduse semnificativ la pacienţii cu sepsis vs. control şi, de asemenea, sunt corelate cu gradul de severitate al sepsisului. In 2016 a fost propusă o nouă definiţie a sepsisului (Sepsis-3). Elementul central în definirea sepsisului este reprezentat de disfuncţia de organ, reprezentând o modificare acută a scorului SOFA ≥ 2 puncte consecutivă unei infecţii. Utilizarea criteriilor SIRS în identificarea pacienţilor cu sepsis a fost abandonată, iar subcategoria "sepsis sever" a fost eliminată. Absenţa biomarkerilor specifici pentru sepsis rămâne o mare problemă şi din acest punct de vedere studiile nu au găsit încă un răspuns. Mai multe miRNAs au fost găsite diferit exprimate la pacienţii cu sepsis, dar majoritatea studiilor publicate până acum au eşuat în a găsi potenţialii biomarkeri care ar putea diferenţia sepsisul de SIRS. O soluţie a acestei probleme pare a fi analiza reţelelor de miRNA în sepsis.
Introduction
With all of the progresses in the field of diagnostic and treatment, sepsis remains the leading cause of death in Intense Care Unit (ICU) in USA with a mortality rate of 28.6% (range 20% to 50%) (1) . Across Europe more than 35% of ICU patients had sepsis at some point during their ICU stay with an overall hospital mortality rate of 24,1% (range 14% to 41%) (2) . Although the mortality rate among patients with sepsis is declining the number of patients dying from sepsis is growing as more patients are affected (3, 4) .
Early diagnostic and evaluation of severity of sepsis with aggressive resuscitation and administration of appropriate antibiotics are associated with improved outcomes (5) .
In 1914, Schottmueller H.6, a student of German physician H. Lennhartz, proposed the first definition of sepsis: "Sepsis is present if a focus has developed from which pathogenic bacteria, constantly or periodically, invade the blood stream in such a way that this causes subjective and objective symptoms" (6) .
In 1992, a North American consensus conference was defining criteria for sepsis and introduced the idea that sepsis is the host's inflammatory response to infection. The first definition of the septic syndrome (Sepsis-1) was based on the concomitant presence of presumed or confirmed infection and at least two Systemic Inflammatory Response Syndrome (SIRS) criteria 7 (Table 1 ). In the same conference severe sepsis was defined as sepsis with organ dysfunction, hypoperfusion or hypotension and septic shock as "persisting sepsis-induced hypotension despite adequate fluid resuscitation" (7) .
In 2001, SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference 8 introduced an updated list of signs and symptoms of sepsis (Sepsis-2), but didn't change definition for sepsis. The primary point of the conference was: "The current concepts of sepsis, severe sepsis, and septic shock seem to be robust definitions and should remain as described 10 years ago" (8) .
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In 2016 a new definition of sepsis (Sepsis-3) was proposed by SCCM/ESICM (9) . Sepsis is now considered a life-threatening organ dysfunction due a dysregulated systemic inflammatory and immune response to microbial invasion that can produce organ injury. The key element of sepsis-induced organ dysfunction is defined by 'an acute change in total SOFA score ≥ 2 points consequent to infection', reflecting an overall mortality rate of approximately 10%" (9) . The use of SIRS criteria as identification of sepsis was abandoned and subcategory of severe sepsis was eliminated. Septic shock was defined as a 'subset of sepsis where underlying circulatory and cellular/ metabolic abnormalities are profound enough to substantially increase mortality'. Criteria identifying these condition include: the need for vasopressors to obtain a MAP ≥ 65mmHg and an increase in lactate concentration > 2 mmol/L. This new definition is mainly focused on the importance to distinguish septic shock from other forms of circulatory shock and underline the detrimental clinical impact of sepsisinduced cellular metabolism abnormalities (9) . Sepsis patients, identified according to the new (Sepsis-3) criteria have higher mortality compared with those identified according with Sepsis-2 criteria. The new definitions select a smaller, but more critically ill, subcategory of patients (10) . The SOFA scoring system is commonly used in intensive care units, but due to its complexity it may delay the time of sepsis identification and diagnosis. A simplified tool to identify patients potentially at risk of dying from sepsis was introduced: quick SOFA (qSOFA) consisting in only three criteria ( Table 2) .
The presence of at least two of these criteria indicates organ dysfunction. The qSOFA score does not require laboratory tests and can be used quickly at the bedside.
The use of qSOFA in detection of patients with sepsis was studied and some authors raised the concern that qSOFA has a poor sensitivity and cannot be used as screening tool for early sepsis, when the treatment is the most effective (11) .
Due to a fact that gold standard for diagnostic and treatment of sepsis is still a matter of debate, a wide spectrum of biomarkers, more than in other diseases, had been proposed for potential use in sepsis, outlying the complex pathophysiology of this condition. More of 180 different sepsis biomarkers have been reported in the literature until 2010 (12) , none of them with sufficient specificity or sensitivity to be introduced in clinical practice. At present, the promising biomarkers of sepsis are procalcitonin, interleukin-6 and C-reactive protein, but neither fulfills the role of an ideal biomarker of sepsis. The search for biomarkers with excellent clinical testing performance goes on (12) (13) (14) (15) (16) .
MicroRNAs (miRNAs) are small noncoding RNAs (ncRNAs), consisting of 19-24 nucleotides with gene regulatory functions. Changes in miRNA expression play an important role in the regulation of the immune response.
Since the discovery of microRNAs (miRNAs) in 1993 (17, 18) more than 2815 miRNAs have been described in humans (19) . A significant number of miRNAs are found at intracellular level. Several studies report the existence of a significant number of miRNAs outside the cell, called circulating miRNAs (20) . Extracellular miRNAs have been identified in several biological fluids, such as blood, urine, saliva, peritoneal fluid, amniotic fluid, bronchial lavage, cerebrospinal fluid, and tears (21) . Published in 2009, the first study reporting the clinical value of circulating miRNAs in sepsis, showed that miR-150 levels in both leukocytes and plasma were significantly reduced in sepsis patients compared with controls and correlated with the level of sepsis severity (22) . Several following studies found lower miR-150 levels in sepsis patients and the correlation with severity of sepsis, suggesting the use of miR-150 as prognostic factor (23, 24) .
miR-223 and miR-146a represent two of the most researched miRNAs involved in the pathogenesis of various diseases. Wang et al. demonstrated that miR-223 and miR-146a are dysregulated in sepsis patients (25) . Serum levels of miR-146a and miR-223 were significantly reduced in sepsis patients compared to SIRS patients and healthy individuals. Importantly, there were no significant changes in miR-223 levels in SIRS patients compared to healthy individuals (26) . miR-223 can be a useful tool to differentiate infectious from non-infectious SIRS. Recently, one study profiled serum miRNAs of 214 sepsis patients (117 survivors and 97 nonsurvivors) found that miR-223 levels were significantly lower in non-survivors compared to survivors (26) .
Until now there are no published papers studying the miRNAs in sepsis patients identified according to new definition. Taking into account that the old definition of sepsis was focusing on inflammation rather than organdysfunction, the interpretation of miRNAs as a biomarkers may be altered. Focused on organ dysfunction, the new sepsis-definition may change the role of miRNAs in diagnosis and treatment of sepsis patients.
Most published research tried and failed to demonstrate the potential role of miRNA as biomarkers that could differentiate sepsis from SIRS because focusing solely on profiling the miRNA signature in plasma/blood cells. A solution to this problem was proposed in 2017 by Vasilescu et al. (20) using the network theory, as a method to describe complex biological systems, building the miRNA network in septic patients and compare it to miRNA network in healthy controls. According to the authors the miRNA network in sepsis is less connected, the miRNAs seem to be "sponged", sequester; hence, the activity of these miRNAs is altered. Understanding the dynamics of miRNA network in sepsis offer the possibility to discover diagnostic and therapeutic strategies targeting components of the immune response.
Conclusion
Early diagnosis, evaluation of severity of sepsis and aggressive treatment are associated with improved outcomes. Sepsis is considered now a life-threatening organ dysfunction due a dysregulated systemic inflammatory and immune response to microbial invasion that can produce organ injury. Septic shock is considered a subset of sepsis where underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality. This new definition is mainly focused on the importance to distinguish septic shock from other forms of circulatory shock and underline the detrimental clinical impact of sepsis-induced cellular metabolism abnormalities. The absence of sepsis specific biomarkers remains an important problem and from this point of view sepsis studies are limited. Several miRNAs were found differentially expressed in sepsis patients, but most of the published studies failed to find miRNA biomarkers that could differentiate sepsis from SIRS. A solution to this problem seems to be building and analyzing miRNA network in sepsis patients.
